February 26, 2015
In this poster presentation, Dr. Chris Parker presented updated safety data from the ALSYMPCA trial. The ALSYMPCA trial was a phase III randomized, double-blind, placebo-controlled trial published in 2013 which demonstrated an overall survival benefit and increased time to a first skeletal-related event with the administration of radium-223 to men with metastatic CRPC with multiple symptomatic bony metastases.
At the time of initial publication and subsequent follow-up studies, radium-223 was found to have a favorable safety profile, owing to decreased depth of penetration of alpha particles, and thus decreased risk for myelosuppression. In this study presenting 3-year safety data, the authors reported that in both the radium-223 and placebo groups, over 90% of patients reported experiencing at least one treatment-related adverse event in the initial treatment period including the time up to 12 weeks from the last injection.